Skip to content
Bayer
-
Bayer secures US$3.4B equity injection from Apollo for LARC contraceptives portfolio
The agreement gives Apollo-managed funds and affiliates a non-controlling interest in a newly created entity that will hold Bayer’s LARC portfolio.
-
Bayer to acquire Perfuse Therapeutics in US$2.45B deal to strengthen its ophthalmology pipeline
The acquisition comes as Bayer seeks to reinforce its position in ophthalmology amid growing biosimilar competition facing Eylea, which it co-developed with Regeneron.